Skip to main content

Advertisement

Fig. 2 | EJNMMI Research

Fig. 2

From: In vivo imaging of early stages of rheumatoid arthritis by α5β1-integrin-targeted positron emission tomography

Fig. 2

Subtype-specific integrin PET imaging in arthritic mice. a, b α5β1 integrin PET using 68Ga-Aquibeprin. c, d αvβ3 integrin PET using 68Ga-Avebetrin. Each of the images ad shows two independent scans of the same mouse (different animals are shown in ad). The arthritic joints are indicated by the arrows. The saturation of the receptor binding capacity by means of co-injection of a large dose (30 nmol) of unlabeled compound (blockade) resulted in a virtually complete reduction of the uptake in arthritic joints for both tracers, confirming the specificity of the PET imaging (a, c). The cross-blockade experiments confirmed the subtype-selectivity of α5β1- and αvβ3 integrin PET: The co-injection of 30 nmol Avebetrin did not substantially affect the α5β1 integrin imaging with 68Ga-Aquibeprin, while the minuscule reduction of the signal is likely related to a residual α5β1 activity (39 nM) of Avebetrin (b). The co-injection of 30 nmol Aquibeprin did not affect αvβ3 integrin imaging with 68Ga-Avebetrin (d)

Back to article page